BeOne Medicines (BEIGF) Liabilities and Shareholders Equity (2016 - 2025)
BeOne Medicines (BEIGF) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $8.2 billion as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 38.3% to $8.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.0 billion through Dec 2025, up 20.88% year-over-year, with the annual reading at $8.2 billion for FY2025, 38.3% up from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $8.2 billion at BeOne Medicines, up from $7.6 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $8.5 billion in Q4 2021, with the low at $5.3 billion in Q3 2021.
- Average Liabilities and Shareholders Equity over 5 years is $6.3 billion, with a median of $5.8 billion recorded in 2024.
- The sharpest move saw Liabilities and Shareholders Equity soared 52.4% in 2021, then tumbled 35.78% in 2022.
- Over 5 years, Liabilities and Shareholders Equity stood at $8.5 billion in 2021, then tumbled by 35.78% to $5.5 billion in 2022, then rose by 5.91% to $5.8 billion in 2023, then grew by 1.99% to $5.9 billion in 2024, then skyrocketed by 38.3% to $8.2 billion in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $8.2 billion, $7.6 billion, and $6.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.